DiaMedica Therapeutics Inc. (DMAC) Free cash flow 2017–2025
DiaMedica Therapeutics Inc. (DMAC) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$29.1MFY2025 · since FY2017: -$3.9M → -$29.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$29.1M | -31.7% |
| FY2024 | -$22.1M | -17.9% |
| FY2023 | -$18.8M | -61.8% |
| FY2022 | -$11.6M | +5.6% |
| FY2021 | -$12.3M | -33.0% |
| FY2020 | -$9.2M | -1.4% |
| FY2019 | -$9.1M | -58.4% |
| FY2018 | -$5.7M | -46.5% |
| FY2017 | -$3.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More DMAC financial trends
DMAC RevenueDMAC Net incomeDMAC Net marginDMAC Gross profitDMAC Gross marginDMAC Operating incomeDMAC Operating marginDMAC Operating cash flowDMAC Capital expendituresDMAC Return on equityDMAC Stock buybacksDMAC Dividends paidDMAC Total assetsDMAC Total liabilitiesDMAC Shareholders’ equityDMAC overview →